Cellectar Biosciences
Cellectar Biosciences, Inc. (Form: 8-K, Received: 11/20/2017 16:03:24)



Washington, D.C. 20549










Date of Report: November 20, 2017
( Date of earliest event reported )


( Exact name of registrant as specified in its charter )





(State or other jurisdiction

of incorporation)


File Number)

(IRS Employer

Identification Number)



3301 Agriculture Drive, Madison, Wisconsin 53716
( Address of principal executive offices )


(608) 441-8120
( Registrant's telephone number, including area code


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐








On November 20, 2017, we issued a press release announcing that we will be presenting at the 10 th Annual LD Micro Main Event on Tuesday, December 5 th at 8:30 AM PT/11:30 AM ET. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.




(d) Exhibits


Number   Title
99.1   Press release dated November 20, 2017, titled “Cellectar Biosciences to Present at the 10th Annual LD Micro Main Event”









Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Dated:  November 20, 2017   CELLECTAR BIOSCIENCES, INC.
  By:   /s/ John P. Hamill
    Name:  John P. Hamill
    Title:  Interim Chief Financial Officer







Exhibit 99.1


Cellectar Biosciences to Present at the 10 th Annual LD Micro Main Event


Madison, Wisc., (November 20, 2017) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will be presenting at the 10 th Annual LD Micro Main Event on Tuesday, December 5 th at 8:30 AM PT/11:30 AM ET. Jim Caruso, president and CEO of Cellectar, will present the company and meet with investors.

The company’s presentation will also be webcast at http://wsw.com/webcast/ldmicro13/clrb/, and will be posted on the company’s website following the conference. The LD Micro Main Event will be held at the Luxe Sunset Bel Air Hotel in Los Angeles. 


About Cellectar Biosciences, Inc.


Cellectar Biosciences (Nasdaq: CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers, even sites of metastases. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 has been designated as an orphan drug by the US FDA and is currently being evaluated in a Phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a Phase 2 clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing proprietary PDCs for targeted delivery of chemotherapeutics and has several preclinical stage product candidates, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit www.cellectar.com.






About LD Micro


LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).


In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.


# # #


This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.


Jules Abraham
JQA Partners, Inc.